Side Effects of Calcium Channel Blockers
The major side effects of calcium channel blockers include hypotension, worsening heart failure, bradycardia, AV block, peripheral edema, headache, dizziness, and flushing, with the specific profile varying by drug subclass. 1
Class-Specific Side Effect Profiles
Dihydropyridines (Nifedipine, Amlodipine, Felodipine, Nicardipine)
Dihydropyridines primarily cause vasodilatory side effects due to their high selectivity for vascular smooth muscle over cardiac tissue. 2
- Peripheral edema (common to all CCBs but particularly prominent with dihydropyridines) 1, 2
- Headache 1, 2
- Dizziness 1, 2
- Flushing 1, 2
- Palpitations 2
- Reflex tachycardia (especially with short-acting formulations like immediate-release nifedipine) 2
- Hypotension 1, 2
- Nausea and constipation (particularly with nifedipine) 1
Non-Dihydropyridines (Verapamil, Diltiazem)
Verapamil and diltiazem have more pronounced cardiac effects due to their action on myocardial contractility and conduction tissue, in addition to vasodilatory effects. 1, 2
- Bradycardia 1, 2
- AV block 1, 2
- Myocardial depression 1
- Worsening heart failure 1, 2
- Hypotension 1, 2
- Dizziness 1
- Flushing 1
- Peripheral edema 1, 2
- Constipation (particularly with verapamil, especially in elderly patients) 2
- Reduced left ventricular contractility 2
Critical Safety Considerations
Contraindications and High-Risk Scenarios
Rapid-release, short-acting dihydropyridines (especially immediate-release nifedipine) must be avoided in the absence of concomitant beta blockade due to increased adverse potential and risk of harm. 1, 3
Verapamil and diltiazem should be avoided in patients with:
- Pulmonary edema 1, 3
- Severe left ventricular dysfunction 1, 3
- Heart failure (may have deleterious effects on outcomes) 2
All non-dihydropyridine CCBs are contraindicated in patients with:
Drug Interactions
Diltiazem and verapamil should not be used in combination with ivabradine due to the risk of severe bradycardia, as all CCBs are metabolized by cytochrome P450 3A4. 2
Verapamil and diltiazem inhibit cytochrome P450 3A4, increasing the likelihood of drug-drug interactions with other compounds metabolized by this enzyme. 5
Serum digoxin levels increase after administration of verapamil and nifedipine, though clinical relevance remains uncertain. 4
Common Pitfalls to Avoid
When combining beta blockers and CCBs for refractory ischemic symptoms, exercise greater caution as they may act synergistically to depress left ventricular function and sinus/AV node conduction. 3
The peripheral edema caused by CCBs is non-volume-dependent and vasodilatory in nature, not related to fluid retention. 6, 7
In patients with heart failure with reduced ejection fraction and atrial fibrillation, avoid all CCBs except amlodipine, as most are contraindicated in this population. 8
Most adverse reactions are predictable from the pharmacological actions of CCBs and can be grouped into vasodilation, negative inotropic effects, conduction disturbances, gastrointestinal effects, and drug interactions. 4